123 related articles for article (PubMed ID: 21048388)
1. [Remarkable improvement of the hip joint lesion in a patient with rheumatoid arthritis by the treatment with anti-TNF-α agents].
Nagare Y; Kinoshita K; Nishisaka F; Saito M; Nonaka T; Funauchi M
Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(5):272-6. PubMed ID: 21048388
[TBL] [Abstract][Full Text] [Related]
2. Repair of radiographic hip joint in juvenile rheumatoid arthritis patients treated with etanercept plus methotrexate.
Remy A; Combe B
Joint Bone Spine; 2014 Oct; 81(5):447-9. PubMed ID: 24746812
[TBL] [Abstract][Full Text] [Related]
3. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
4. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
5. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
6. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
Tse SM; Laxer RM; Babyn PS; Doria AS
J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
[TBL] [Abstract][Full Text] [Related]
7. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
9. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis.
Hugle B; Burgos-Vargas R; Inman RD; O'Shea F; Laxer RM; Stimec J; Whitney-Mahoney K; Duvnjak M; Anderson M; Tse SM
Clin Exp Rheumatol; 2014; 32(3):424-31. PubMed ID: 24387974
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency.
Momeni M; Mehta AP; Katz JD
J Clin Rheumatol; 2005 Jun; 11(3):180-2. PubMed ID: 16357744
[No Abstract] [Full Text] [Related]
12. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
[TBL] [Abstract][Full Text] [Related]
13. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
[TBL] [Abstract][Full Text] [Related]
14. Juvenile idiopathic arthritis: current and future treatment options.
Martini G; Zulian F
Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
[TBL] [Abstract][Full Text] [Related]
15. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
16. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR; Keating GM
Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
[TBL] [Abstract][Full Text] [Related]
17. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
Katsicas MM; Russo RA
Clin Exp Rheumatol; 2005; 23(4):545-8. PubMed ID: 16095128
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
19. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]